Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM) for Diagnosis and Management of Bladder Outlet Obstruction in Men
试验速览
- 阶段
- 不适用
- 入组人数
- 820
- 试验地点
- 1
- 主要终点
- International Prostate Symptom Score
研究概览
简要总结
Background and study aims: The prostate gland sits around the exit of the bladder in men. As men get older, the prostate grows, and this can narrow the exit from the bladder, so that there is restriction of flow. As a result, some men develop difficulty passing urine (voiding) as they age. For these men, prostate surgery can be helpful by removing the part of the prostate causing the narrowing, so that flow improves. However, for some men, almost identical symptoms of difficulty passing urine are due to underactive bladder. In other words, the bladder contraction is too weak, and is not effective at expelling the urine. This is a smaller group, but important, as these men may have no improvement after prostate surgery, while being exposed to risk of complications of surgery. Medical assessment of men with voiding problems typically involves discussing the symptoms, doing a physical examination of the prostate and measuring the urine flow rate. In many NHS hospitals, these are the only tests done before deciding whether to proceed to prostate surgery. In effect, voiding symptoms are presumed to be a result of prostate enlargement for these men, since it is the more common problem compared with bladder underactivity. However, this approach cannot identify which men actually have bladder underactivity as the cause of their voiding symptoms. So, in some hospitals an extra test is used, called urodynamics. Urodynamics is done to measure how much pressure the bladder generates when passing urine, because a high pressure shows the problem is obstruction, and a low pressure shows it is bladder weakness. Urodynamics involves gently putting a small tube into the bladder via the penis to measure the bladder pressure, and to fill the bladder with a sterile fluid (saline). Another small tube is gently placed into the rectum, via the anus, to measure abdominal pressures. Measuring abdominal pressure is necessary because any change in abdominal pressure can affect bladder pressure, and if the test did not allow for this it could give a misleading result. Urodynamics is safe, but some men find it uncomfortable or undignified, and a few develop urine infection afterwards. No studies have been conducted so far to tell us which of these two approaches to assessing men with voiding urinary problems is better overall.
UPSTREAM consists of two phases: "UPSTREAM - Phase I" was a pragmatic, two-arm, multicentre, randomised controlled trial (RCT) to determine the clinical and cost-effectiveness of invasive urodynamics (UDS) for the diagnosis and management of bladder outlet obstruction in men. Men from 26 urology departments of NHS Hospitals in England who had bothersome lower urinary tract symptoms (LUTS) and were seeking further treatment, which may have included surgery, were randomised to one of two study arms; 'Routine Care' (as per the NICE diagnostic pathway), or routine care plus UDS ('Urodynamics'), which is currently optional. The design was utilised to establish noninferiority in symptom severity (International Prostate Symptom Score [IPSS]) 18-months post-randomisation. The primary outcome was IPSS at 18-months post-randomisation, and a key secondary outcome was the influence of UDS on rates of bladder outlet surgery. The RCT started 01 April 2014 and ended 30 September 2018.
In 2018, we were awarded an extension to conduct a further (long term) follow up of UPSTREAM participants, five years post-randomisation; "UPSTREAM - Phase II". We aim to identify: the symptom outcomes of treatment; definitive surgery rates in the two study arms; and the long-term impact of LUTS and its therapy. The focus will continue to be on effectiveness and patient outcomes as per the original commissioning brief. "UPSTREAM - Phase II" started 01 July 2019 and has a planned end date of 30 June 2022.
详细描述
The aim of the UPSTREAM trial ("UPSTREAM - Phase I") was to determine whether a care pathway including invasive urodynamics is no worse for men in terms of symptom outcome than one in which it is not included, at 18 months after randomisation. We also aimed to establish whether inclusion of invasive urodynamics reduces rates of bladder outlet surgery as a main secondary outcome.
The following men were invited to participate (inclusion criterion); • Men seeking further treatment for their bothersome lower urinary tract symptoms (LUTS) which may include surgery
Men were not invited to participate (exclusion criteria) if they:
- were unable to pass urine without a catheter (urinary retention)
- had a relevant neurological disease, such as a stroke
- were undergoing treatment for prostate or bladder cancer
- had previously had prostate surgery
- were not medically fit for surgery, or were unable to complete outcome assessments
- did not consent to be assigned at random to one of the pathways
We compared the two methods of investigation by finding out whether the men had similar relief of their symptoms, by measuring the change in the prostate symptom score (IPSS) in the two groups at 18 months after randomisation (primary outcome).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •"UPSTREAM - Phase I":
- •Inclusion Criteria:
- •Men seeking further treatment for their bothersome lower urinary tract symptoms (LUTS) which may include surgery
排除标准
- •unable to pass urine without a catheter (urinary retention)
- •relevant neurological disease, such as a stroke
- •undergoing treatment for prostate or bladder cancer
- •previously had prostate surgery
- •not medically fit for surgery, or are unable to complete outcome assessments
- •do not consent to be assigned at random to one of the pathways
- •"UPSTREAM - Phase II":
- •Inclusion criteria:
- •PROMS (questionnaire) study component:
- •Men randomised (enrolled) to the UPSTREAM trial (Phase I) who were willing to be contacted for long term follow up, as indicated on their original (Phase I) consent form.
- •NHS Digital data extraction study component:
- •Men randomised (enrolled) to the UPSTREAM trial (Phase I).
- •Exclusion criteria:
- •PROMS (questionnaire) study component:
- •Patients who are not already randomised (enrolled) to the UPSTREAM trial (Phase I)
- •UPSTREAM (Phase I) participants who:
- •are not willing to be contacted about long term follow up 2.
- •have withdrawn trial participation, or at least withdrawn permission to be contacted in the future for long term follow up, at the time of their 18-month timepoint 2.
- •do not consent and/or are not willing or able to comply with essential study procedures of this further follow up (UPSTREAM - Phase II)
- •NHS Digital data extraction study component:
- •Patients who are not already randomised (enrolled) to the UPSTREAM trial (Phase I)
- •UPSTREAM (Phase I) participants who have withdrawn permission for the study to continue to access sections of their medical notes and NHS records, ONS and NHS Central registers information, at the time of their 18-month timepoint
研究组 & 干预措施
Usual care
Usual diagnostics in male LUTS; flow rate test, symptom score and bladder diary
干预措施: Usual care (Procedure)
Urodynamics
Invasive urodynamic cystometry including pressure flow studies, along with usual diagnostics in male LUTS
干预措施: Urodynamics (Procedure)
Urodynamics
Invasive urodynamic cystometry including pressure flow studies, along with usual diagnostics in male LUTS
干预措施: Usual care (Procedure)
结局指标
主要结局
International Prostate Symptom Score
时间窗: 18 months
Primary clinical outcome: difference in lower urinary tract symptom (LUTS) between the two arms at 18 months, measured with the International Prostate Symptom Score (IPSS)
次要结局
- Cost-effectiveness analyses(18 months)
- Maximum urinary flow rate(18 months)
- Surgery rate(5 years post randomisation ("UPSTREAM - Phase II"))
- International Consultation on Incontinence Questionnaires(18 months)
- Adverse events(18 months)
- EQ-5D-5L(5 years post randomisation ("UPSTREAM - Phase II"))
- International Prostate Symptom Score (IPSS)(5 years post randomisation ("UPSTREAM - Phase II"))
- Measures from the International Consultation on Incontinence Questionnaires (ICIQ) regarding male lower urinary tract symptoms (LUTS) severity/ bother(5 years post randomisation ("UPSTREAM - Phase II"))
- Measures from the International Consultation on Incontinence Questionnaires Measures from the International Consultation on Incontinence Questionnaires (ICIQ) regarding regarding sexual function(5 years post randomisation ("UPSTREAM - Phase II"))
- Quality of Life (QoL)(5 years post randomisation ("UPSTREAM - Phase II"))
- Surgery rate(18 months)
- EQ-5D-5L(18 months)
